Cargando…

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

BACKGROUND: Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). OBJECTIVE: To examine the association between use of PCSK9 inhibitors with and without concurrent statins and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Lingqing, Chen, Congqin, Yang, Yongkuan, Fang, Jie, Cao, Longxing, Liu, Yige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808238/ https://www.ncbi.nlm.nih.gov/pubmed/35140810 http://dx.doi.org/10.1155/2022/9866486

Ejemplares similares

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
por: Huang, Liting, et al.
Publicado: (2021)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
por: Kong, Wenqiang, et al.
Publicado: (2023)

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
por: Huang, Jing, et al.
Publicado: (2020)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
por: Li, Hailong, et al.
Publicado: (2023)

Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
por: Chen, Congqin, et al.
Publicado: (2022)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
por: Gui, Xiujuan, et al.
Publicado: (2023)

Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022
por: Huang, Haining, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase
por: Noseda, Roberta, et al.
Publicado: (2021)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
por: Han, Nayoung, et al.
Publicado: (2020)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis( )
por: Chuma, Masayuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uile6g2phqbh9lemuqm8ipdq7j